Tyler Cassidy

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 11

Top Topics

Antiretroviral Therapy

Human Immunodeficiency Virus

Monoclonal Antibody

Top Venues

PLoS computational biology

Nature medicine

Bulletin of mathematical biology

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Tyler Cassidy, Kathryn E Stephenson, Dan H Barouch, Alan S Perelson
Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1. PLoS computational biology 20 (3) (2024)
Tyler Cassidy, Kathryn E Stephenson, Dan H Barouch, Alan S Perelson
Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1. PLoS computational biology 20 (3) (2024)
Tyler Cassidy, Kathryn E Stephenson, Dan H Barouch, Alan S Perelson
Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1. PLoS computational biology 20 (3) (2024)
Tyler Cassidy, Kathryn E Stephenson, Dan H Barouch, Alan S Perelson
Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1. PLoS computational biology 20 (3) (2024)
Tyler Cassidy, Kathryn E Stephenson, Dan H Barouch, Alan S Perelson
Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1. PLoS computational biology 20 (3) (2024)
Tyler Cassidy, Kathryn E Stephenson, Dan H Barouch, Alan S Perelson
Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1. PLoS computational biology 20 (3) (2024)
Tyler Cassidy
A Continuation Technique for Maximum Likelihood Estimators in Biological Models. Bulletin of mathematical biology 85 (10) (2023)
Tyler Cassidy, Daniel Nichol, Mark Robertson-Tessi, Morgan Craig, Alexander A R A Anderson
The role of memory in non-genetic inheritance and its impact on cancer treatment resistance. PLoS computational biology 17 (8) (2021)
Adrianne L Jenner, Tyler Cassidy, Katia Belaid, Marie-Claude Bourgeois-Daigneault, Morgan Craig
In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity. Journal for immunotherapy of cancer 9 (2) (2021)
Kathryn E Stephenson, Boris Julg, C Sabrina Tan, Rebecca Zash, Stephen R Walsh, Charlotte-Paige Rolle, Ana N Monczor, Sofia Lupo, Huub C Gelderblom, Jessica L Ansel, Diane G Kanjilal, Lori F Maxfield, Joseph Nkolola, Erica N Borducchi, Peter Abbink, Jinyan Liu, Lauren Peter, Abishek Chandrashekar, Ramya Nityanandam, Zijin Lin, Alessandra Setaro, Joseph Sapiente, Zhilin Chen, Lisa Sunner, Tyler Cassidy, Chelsey Bennett, Alicia Sato, Bryan T Mayer, Alan S Perelson, Allan deCamp, Frances H Priddy, Kshitij Wagh, Elena E Giorgi, Nicole L Yates, Roberto C Arduino, Edwin DeJesus, Georgia D Tomaras, Michael S Seaman, Bette Korber, Dan H Barouch
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nature medicine 27 (10) (2021)
Tyler Cassidy, Morgan Craig
Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization. PLoS computational biology 15 (11) (2019)